What is VitaDAO?
VitaDAO operates as a Decentralized Autonomous Organization (DAO) dedicated to community-governed and decentralized drug development. The collective's primary objective is to accelerate research and development (R&D) within the longevity sector, aiming to extend human life and healthspan. To achieve these ambitious goals, VitaDAO strategically funds and digitizes research through the creation of IP-NFTs, subsequently spinning out new biotech ventures.
How much funding has VitaDAO raised?
VitaDAO has raised a total of $4.1M across 1 funding round:
Other Financing Round
$4.1M
Other Financing Round (2023): $4.1M with participation from L1 Digital, Pfizer Ventures, and Shine Capital
Key Investors in VitaDAO
L1 Digital
At L1 Digital investments are implemented through crypto native managers, co-investments and directs.
Pfizer Ventures
Pfizer Ventures is the corporate venture capital arm of Pfizer, investing in innovative companies that align with Pfizer's strategic interests in drug development and healthcare.
Shine Capital
Shine Capital is an early-stage venture capital firm that collaborates with innovative and determined entrepreneurs to create iconic businesses. The firm focuses on partnering with individuals who demonstrate creativity and conviction in their ventures.
What's next for VitaDAO?
The recent major enterprise-level funding positions VitaDAO for accelerated growth and expanded operational capacity. This strategic backing is expected to fuel further innovation in longevity R&D, enabling the DAO to pursue more ambitious projects and potentially launch additional biotech spin-offs. The focus on IP-NFTs suggests a continued commitment to novel funding and intellectual property management models within the life sciences.
See full VitaDAO company page
